Am Regent patent expiration
1. Dexferrum patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5624668 | AM REGENT | Iron dextran formulations |
Sep, 2015
(8 years ago) | |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 23 February, 1996
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
DEXFERRUM family patents
2. Injectafer patent expiration
INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519252 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(10 months ago) | |
| US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(10 months ago) | |
| US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(10 months ago) | |
| US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(10 months ago) | |
| US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(10 months ago) | |
| US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364260 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 25, 2016 |
| New Strength(NS) | Apr 28, 2024 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method to treat iron deficiency in adults weighing at least 40 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provi...
Dosage: SOLUTION
How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage
INJECTAFER family patents
3. Multrys patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975022 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...
Dosage: SOLUTION
More Information on Dosage
MULTRYS family patents
4. Selenious Acid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using SELENIOUS ACID ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 August, 2021
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SELENIOUS ACID family patents
5. Tralement patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975022 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: Adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or cont...
Dosage: SOLUTION
More Information on Dosage
TRALEMENT family patents